DBV Technologies Investor Relations Material
Latest events
Study Update
DBV Technologies
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from DBV Technologies S.A.
Access all reports
DBV Technologies S.A. is a French biopharmaceutical company focused on developing therapies for food allergies using its proprietary epicutaneous immunotherapy (EPIT) technology platform. The company's lead product candidate is designed to treat peanut allergies by delivering allergens through the skin to desensitize patients while minimizing the risk of severe allergic reactions. DBV's non-invasive approach aims to provide safe and effective treatments for patients with food allergies, addressing a significant unmet need in allergy management. The company is headquartered in Montrouge, France, and its shares are listed on Euronext Paris and the Nasdaq.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
DBV
Country
🇫🇷 France